Cargando…

The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial

BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are commonly prescribed to patients with hypertension. These drugs are cardioprotective in addition to their blood pressure-lowering effects. However, it is debatable whether hypertensive patients who p...

Descripción completa

Detalles Bibliográficos
Autores principales: Misra, Satyajeet, Parida, Satyen, Sahajanandan, Raj, Behera, Bikram Kishore, Senthilnathan, Muthapillai, Mariappan, Ramamani, Chandy, Tony Thomson
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386985/
https://www.ncbi.nlm.nih.gov/pubmed/35978368
http://dx.doi.org/10.1186/s13063-022-06616-y
_version_ 1784769929598205952
author Misra, Satyajeet
Parida, Satyen
Sahajanandan, Raj
Behera, Bikram Kishore
Senthilnathan, Muthapillai
Mariappan, Ramamani
Chandy, Tony Thomson
author_facet Misra, Satyajeet
Parida, Satyen
Sahajanandan, Raj
Behera, Bikram Kishore
Senthilnathan, Muthapillai
Mariappan, Ramamani
Chandy, Tony Thomson
author_sort Misra, Satyajeet
collection PubMed
description BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are commonly prescribed to patients with hypertension. These drugs are cardioprotective in addition to their blood pressure-lowering effects. However, it is debatable whether hypertensive patients who present for non-cardiac surgery should continue or discontinue these drugs preoperatively. Continuing the drugs entails the risk of perioperative refractory hypotension and/or angioneurotic oedema, while discontinuing the drugs entails the risk of rebound hypertension and myocardial ischaemia. The aim of this study is to evaluate the effect of continuation vs withholding of ACEIs/ARBs on mortality and other major outcomes in hypertensive patients undergoing elective non-cardiac surgery. METHODS: The continuing vs withholding of ACEIs/ARBs in patients undergoing non-cardiac surgery is a prospective, multi-centric, open-label randomised controlled trial. Two thousand one hundred hypertensive patients receiving ACEIs/ARBs and planned for elective non-cardiac surgery will be enrolled. They will be randomised to either continue the ACEIs/ARBs including on the day of surgery (group A) or to withhold it 24–36 h before surgery (group B). The primary endpoint will be the difference in the composite outcome of all-cause in-hospital/30-day mortality and major adverse cardiovascular and non-cardiovascular events. Secondary endpoints will be to evaluate the differences in perioperative hypotension, angioneurotic oedema, myocardial injury, ICU and hospital stay. The impact of the continuation vs withholding of the ACEIs/ARBs on the incidence of case cancellation will also be studied. DISCUSSION: The results of this trial should provide sufficient evidence on whether to continue or withhold ACEIs/ARBs before major non-cardiac surgery. TRIAL REGISTRATION: Clinical Trials Registry of India CTRI/2021/01/030199. Registered on 4 January 2021 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06616-y.
format Online
Article
Text
id pubmed-9386985
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93869852022-08-19 The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial Misra, Satyajeet Parida, Satyen Sahajanandan, Raj Behera, Bikram Kishore Senthilnathan, Muthapillai Mariappan, Ramamani Chandy, Tony Thomson Trials Study Protocol BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs) are commonly prescribed to patients with hypertension. These drugs are cardioprotective in addition to their blood pressure-lowering effects. However, it is debatable whether hypertensive patients who present for non-cardiac surgery should continue or discontinue these drugs preoperatively. Continuing the drugs entails the risk of perioperative refractory hypotension and/or angioneurotic oedema, while discontinuing the drugs entails the risk of rebound hypertension and myocardial ischaemia. The aim of this study is to evaluate the effect of continuation vs withholding of ACEIs/ARBs on mortality and other major outcomes in hypertensive patients undergoing elective non-cardiac surgery. METHODS: The continuing vs withholding of ACEIs/ARBs in patients undergoing non-cardiac surgery is a prospective, multi-centric, open-label randomised controlled trial. Two thousand one hundred hypertensive patients receiving ACEIs/ARBs and planned for elective non-cardiac surgery will be enrolled. They will be randomised to either continue the ACEIs/ARBs including on the day of surgery (group A) or to withhold it 24–36 h before surgery (group B). The primary endpoint will be the difference in the composite outcome of all-cause in-hospital/30-day mortality and major adverse cardiovascular and non-cardiovascular events. Secondary endpoints will be to evaluate the differences in perioperative hypotension, angioneurotic oedema, myocardial injury, ICU and hospital stay. The impact of the continuation vs withholding of the ACEIs/ARBs on the incidence of case cancellation will also be studied. DISCUSSION: The results of this trial should provide sufficient evidence on whether to continue or withhold ACEIs/ARBs before major non-cardiac surgery. TRIAL REGISTRATION: Clinical Trials Registry of India CTRI/2021/01/030199. Registered on 4 January 2021 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13063-022-06616-y. BioMed Central 2022-08-17 /pmc/articles/PMC9386985/ /pubmed/35978368 http://dx.doi.org/10.1186/s13063-022-06616-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Misra, Satyajeet
Parida, Satyen
Sahajanandan, Raj
Behera, Bikram Kishore
Senthilnathan, Muthapillai
Mariappan, Ramamani
Chandy, Tony Thomson
The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial
title The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial
title_full The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial
title_fullStr The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial
title_full_unstemmed The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial
title_short The effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial
title_sort effect of continuing versus withholding angiotensin-converting enzyme inhibitors/angiotensin ii receptor blockers on mortality and major adverse cardiovascular events in hypertensive patients undergoing elective non-cardiac surgery: study protocol for a multi-centric open-label randomised controlled trial
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9386985/
https://www.ncbi.nlm.nih.gov/pubmed/35978368
http://dx.doi.org/10.1186/s13063-022-06616-y
work_keys_str_mv AT misrasatyajeet theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised
AT paridasatyen theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised
AT sahajanandanraj theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised
AT beherabikramkishore theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised
AT senthilnathanmuthapillai theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised
AT mariappanramamani theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised
AT chandytonythomson theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised
AT theeffectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomised
AT misrasatyajeet effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon
AT paridasatyen effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon
AT sahajanandanraj effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon
AT beherabikramkishore effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon
AT senthilnathanmuthapillai effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon
AT mariappanramamani effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon
AT chandytonythomson effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon
AT effectofcontinuingversuswithholdingangiotensinconvertingenzymeinhibitorsangiotensiniireceptorblockersonmortalityandmajoradversecardiovasculareventsinhypertensivepatientsundergoingelectivenoncardiacsurgerystudyprotocolforamulticentricopenlabelrandomisedcon